Researchers at Swedish institutions have cracked a stubborn problem that has plagued stem cell therapy for years: reliably producing functional insulin-producing cells that actually work in the body. The breakthrough, published in Stem Cell Reports, demonstrates that these lab-grown cells can restore blood sugar control in diabetic mice, opening a new pathway toward treating type 1 diabetes in humans.
Type 1 diabetes strikes when the immune system mistakenly destroys the pancreas's insulin-producing cells. Without insulin, the body cannot process glucose properly, leaving patients dependent on daily injections. Scientists have long theorized that replacing those lost cells could be transformative, but earlier attempts to grow them from stem cells in the laboratory produced wildly inconsistent results.
The Swedish team solved that consistency problem by refining the culture process and allowing cells to form natural three-dimensional clusters. This approach dramatically reduced the production of unwanted cell types and improved how well the lab-grown cells responded to glucose signals. The result: insulin-producing cells that are both more mature and more functional than anything previously achieved.
When these cells were transplanted into diabetic mice, they gradually matured and restored the animals' natural ability to regulate blood sugar over several months. Researchers placed the cells in the mice's eye to monitor their development in real time, a minimally invasive technique that allowed them to track performance without constant biopsies.
Per-Olof Berggren, a professor at Karolinska Institutet's Department of Molecular Medicine and Surgery, emphasized the clinical significance: the cells derived from multiple human stem cell lines with high reliability, opening the door to patient-specific therapies that could reduce immune rejection in transplant recipients.
The achievement addresses two obstacles that have repeatedly derailed stem cell diabetes treatments. The first is that lab cultures typically produce a mixed bag of cell types, some useful and some harmful. The second is that cells grown this way usually remain too immature to sense and respond to glucose properly. By tackling both problems simultaneously, the Swedish researchers have created a template that other teams may now replicate.
Clinical trials for stem cell therapies in type 1 diabetes are already underway, but most have stumbled on these exact issues. Researchers say the new protocol could accelerate those programs and move closer to actual patient treatment within the next several years.
The work was a collaboration between Karolinska Institutet and KTH Royal Institute of Technology, with funding from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Novo Nordisk Foundation, and other major Swedish and European research bodies.
Author Jessica Williams: "This is the kind of methodical, incremental progress that actually gets to the clinic, not the flashy promises that disappear when tested in humans."
Comments